Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 Net Cash per Share is $0.22 as of Jun. 2026, which is 99% below its 10-year median of 20.84. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.16 (Fairly Valued). The stock has 3 warning signs investors should review. Among 257 Drug Manufacturers companies, BioGaia AB ranks worse than 89.11% on this metric.
BioGaia AB (OTCPK:BGLAF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
BioGaia AB Net Cash per Share Related Terms
BioGaia AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
BioGaia AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Net Cash per Share of $0.22 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on BioGaia AB and its competitors. This is 99% below median its historical median of 20.84. Over the past decade, BioGaia AB's Net Cash per Share has ranged from 6.19 to 254.71. According to the industry distribution chart, BioGaia AB ranks #229 out of 257 companies in the Drug Manufacturers industry, placing it in the top 89.1%.
Is BioGaia AB's Net Cash per Share too high?
BioGaia AB's current Net Cash per Share of $0.22 is 99% below median its 10-year median of 20.84. Over the past 10 years, this metric has ranged from a low of 6.19 to a high of 254.71. The Drug Manufacturers industry median Net Cash per Share is 7.97. BioGaia AB's value of $0.22 is 97.2% below this industry median. Based on the distribution chart, BioGaia AB ranks #229 out of 257 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Net Cash per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #229 out of 257 companies for Net Cash per Share. This places BioGaia AB in the lower half of its industry. The industry median Net Cash per Share is 7.97. BioGaia AB's value of $0.22 is 97.2% below this benchmark. Historically, BioGaia AB's own Net Cash per Share has ranged from 6.19 to 254.71 over the past decade. While the company's 10-year median is 20.84 vs. the industry median of 7.97, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 7.97, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Net Cash per Share of $0.22 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 7.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Net Cash per Share is $0.22, which is 99% below median its own 10-year median of 20.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.16, compared to a current price of $12.20 — trading 7.3% below its estimated fair value. The current Net Cash per Share is $0.22, which is 99% below median its 10-year median of 20.84 and 97.2% below the Drug Manufacturers industry median of 7.97. BioGaia AB's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Net Cash per Share is $0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 7.3% below its estimated GF Value™ of $13.16.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Net Cash per Share: $0.22 (99% below median its 10-year median of 20.84)
GF Value™: $13.16 vs. price of $12.20 (7.3% below fair value)
Industry Position: 97.2% below the Drug Manufacturers median (#229 of 257)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
